Cambridge Cognition Holdings Plc (GB:COG)
LSE:COG
Top Page
Cambridge Cognition Holdings
(LSE:COG)
Select Model
Select Model
Rating:52Neutral
Price Target:
36.00 p
▲(28.57% Upside)
Action:UpgradedDate:01/27/26
Overall score reflects weak financial performance driven by declining revenue, ongoing losses, and negative operating/free cash flow, partially offset by improved equity on the balance sheet. Technicals are mixed (short-term strength but longer-term downtrend and overbought RSI), while valuation is constrained by loss-making results and no stated dividend yield.
Positive Factors
High gross margins from software products
An 81.1% gross margin indicates a software-centric, scalable offering with low incremental costs per additional user. This margin profile supports reinvestment in R&D, clinical validation and commercialisation, providing durable margin leverage as revenue recovers or grows over the medium term.
Negative Factors
Material revenue decline
A 2024 revenue drop represents weakening top-line traction and reduces the company's ability to absorb fixed costs. Continued revenue shrinkage undermines operating leverage, risks eroding customer momentum and makes return to profitable scale more challenging absent clear growth drivers.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins from software products
An 81.1% gross margin indicates a software-centric, scalable offering with low incremental costs per additional user. This margin profile supports reinvestment in R&D, clinical validation and commercialisation, providing durable margin leverage as revenue recovers or grows over the medium term.
Read all positive factors
Cambridge Cognition Holdings (COG) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£17.23M
Dividend YieldN/A
Average Volume (3M)32.00K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-30.77%
EPS Growth-6.97%
CountryUK
Employees119
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding46,629,700
10 Day Avg. Volume24,264
30 Day Avg. Volume32,004
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.31
Price to Sales (P/S)1.40
P/FCF Ratio-4.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£56.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£12.13M
Cambridge Cognition Holdings Business Overview & Revenue Model
Company Description
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, a...
How the Company Makes Money
Cambridge Cognition generates revenue primarily through the sale of its software products and licensing agreements. The company earns income by providing its CANTAB assessments to clinical and academic institutions, facilitating cognitive testing ...
Cambridge Cognition Holdings Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
60
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.05M | 10.34M | 13.52M | 12.61M | 10.09M | 6.74M |
| Gross Profit | 7.25M | 8.39M | 10.80M | 9.32M | 8.08M | 5.42M |
| EBITDA | -563.00K | -542.00K | -2.62M | -514.00K | 412.00K | -502.00K |
| Net Income | -1.67M | -1.78M | -3.51M | -409.00K | 450.00K | -438.00K |
Balance Sheet | ||||||
| Total Assets | 11.73M | 13.03M | 14.23M | 15.11M | 12.54M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 428.00K | 1.30M | 3.23M | 8.32M | 6.81M | 3.05M |
| Total Debt | 1.48M | 1.91M | 2.56M | 18.00K | 18.00K | 98.00K |
| Total Liabilities | 9.40M | 9.67M | 12.95M | 15.01M | 11.91M | 6.21M |
| Stockholders Equity | 2.33M | 3.36M | 1.28M | 95.00K | 632.00K | 57.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.76M | -3.09M | -5.00M | 1.49M | 3.88M | 972.00K |
| Operating Cash Flow | -1.75M | -3.08M | -4.97M | 1.68M | 3.93M | 1.01M |
| Investing Cash Flow | 30.00K | 50.00K | -3.02M | -189.00K | -105.00K | -42.00K |
| Financing Cash Flow | -1.15M | 1.13M | 2.88M | -132.00K | -86.00K | 1.16M |
Cambridge Cognition Holdings Technical Analysis
Neutral
28.00
Price Trends
38.19
Negative
34.34
Positive
33.59
Positive
Market Momentum
-0.99
Positive
41.34
Neutral
23.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:COG, the sentiment is Neutral. The current price of 28 is below the 20-day moving average (MA) of 39.08, below the 50-day MA of 38.19, and below the 200-day MA of 33.59, indicating a neutral trend. The MACD of -0.99 indicates Positive momentum. The RSI at 41.34 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:COG.
Cambridge Cognition Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £38.99M | -13.46 | 10.00% | ― | ― | ― | |
57 Neutral | £123.51M | -5.17 | -3.95% | ― | 31.83% | 46.59% | |
52 Neutral | £17.23M | -3.33 | -58.72% | ― | -30.77% | -6.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.30M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
40 Underperform | £8.80M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £16.18M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:COG
Cambridge Cognition Holdings
37.00
-2.00
-5.13%
GB:IXI
IXICO plc
7.88
-0.38
-4.55%
GB:OBD
Oxford BioDynamics
0.21
-0.28
-57.29%
GB:KOO
Kooth
107.50
-29.00
-21.25%
GB:DXRX
Diaceutics
146.00
23.50
19.18%
GB:APTA
Aptamer Group Plc
0.60
0.34
130.77%
Cambridge Cognition Holdings Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Cambridge Cognition boosts order book and expands into healthcare as 2025 sales surge
Positive
Jan 19, 2026
Cambridge Cognition reported a strong rebound in commercial momentum for 2025, with new sales orders surging 73% to £12.8m and the year-end order book rising 25% to £16.9m, even as reported revenues declined 10% to about £9.4m due t...
Regulatory Filings and ComplianceShareholder Meetings
Cambridge Cognition Appoints New Auditor to Enhance Financial Oversight
Neutral
Nov 5, 2025
Cambridge Cognition Holdings has appointed Cooper Parry Group Limited as its new external auditor following a competitive tender process, replacing Crowe UK LLP. This change is part of the company’s efforts to ensure robust financial oversig...
Business Operations and StrategyExecutive/Board Changes
Cambridge Cognition Announces Key Board Appointments to Drive Growth
Positive
Nov 5, 2025
Cambridge Cognition Holdings has announced significant changes to its board of directors, appointing Rob Baker as CEO and Ronald Openshaw as CFO. These appointments are part of the company’s ongoing growth strategy, with Baker bringing exten...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.